Adicet Bio
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 143
- Market Cap
- -
- Website
- http://www.adicetbio.com
Clinical Trials
4
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
A Phase 1/2 Trial of ADI-270 in ccRCC
- Conditions
- Clear Cell Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2024-06-28
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Adicet Therapeutics
- Target Recruit Count
- 60
- Registration Number
- NCT06480565
- Locations
- 🇺🇸
Adicet Clinical Trials, Redwood City, California, United States
A Phase 1 Study of ADI-001 in Autoimmune Disease
- Conditions
- Lupus NephritisIdiopathic Inflammatory MyopathiesAutoimmune DiseasesSystemic Sclerosis (SSc)ANCA-Associated Vasculitis (AAV)Systemic Lupus Erythematosus (SLE)Stiff Person Syndrome
- Interventions
- First Posted Date
- 2024-04-19
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Adicet Therapeutics
- Target Recruit Count
- 180
- Registration Number
- NCT06375993
- Locations
- 🇺🇸
Adicet Clinical Trials, Redwood City, California, United States
Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells
- Conditions
- Lymphoma, FollicularLymphoma, Non-HodgkinLymphoma, Mantle-CellMarginal Zone LymphomaPrimary Mediastinal B-cell LymphomaDiffuse Large B Cell Lymphoma
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2022-06-09
- Lead Sponsor
- Adicet Therapeutics
- Target Recruit Count
- 50
- Registration Number
- NCT04911478
- Locations
- 🇺🇸
Stanford University Medical Center, Stanford, California, United States
🇺🇸Norton Cancer Institute, Louisville, Kentucky, United States
🇺🇸Baylor Scott & White Research Institute, Dallas, Texas, United States
A Phase 1 Study of ADI-001 in B Cell Malignancies
- Conditions
- Lymphoma, Non-HodgkinLymphoma, Mantle-CellMarginal Zone LymphomaPrimary Mediastinal B-cell LymphomaDiffuse Large B Cell LymphomaLymphoma, Follicular
- Interventions
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Adicet Therapeutics
- Target Recruit Count
- 34
- Registration Number
- NCT04735471
- Locations
- 🇺🇸
Baylor Scott & White Research Institute, Dallas, Texas, United States
🇺🇸Stanford University Medical Center, Stanford, California, United States
🇺🇸University of Miami- Sylvester Comprehensive Cancer Center, Miami, Florida, United States